Sears-Army clothing logo (from Advertising Age)Sears has entered into a first-ever deal with the United States Military to market a new line of officially sanctioned, military-styled clothing to men, women and boys. The military has officially licensed a "soldier chic" line of clothing to Sears called the "All American Army Brand First Infantry Division" collection. The garb, to be launched in 550 Sears stores in October -- just in time for the holiday season -- consists of "authentic lifestyle reinterpretations" of regulation uniforms and military-issued gear like T-shirts, hooded sweatshirts, denim and other outerwear. The partnership is part of a marketing strategy to raise the public profile of the U.S. military. Sears already carries some military-themed merchandise on its Web site, like a Modern Military Figure Special Forces Soldier toy for ages 8 and up, a musical DVD titled "Death Chants, Breakdowns and Military Waltzes, Vol. 2," which lists song titles like "Cadaver Recovery Man" and "Mud & Guts," and a Self-esteem Zip Military Style Vest for Juniors.

The Colombian government will pay U.S. lobbyist Andrew J. Samet another $45,000, "to present Colombia's track record on labor issues to Congress, non-governmental organizations and labor unions." The new contract is similar to Samet's earlier work to push the U.S. - Colombia Free Trade Agreement, on which the Center for Media and Democracy previously reported. Samet served as deputy under secretary for labor under President Bill Clinton and later co-founded the Sorini, Samet & Associates lobbying firm. Samet "was responsible for the North American Agreement on Labor Cooperation," an addition to the North American Free Trade Agreement with Mexico and Canada meant to address concerns about workers rights.

MoveOn, Media Matters and liberal blogs have launched a campaign against Associated Press Washington bureau chief Ron Fournier, "for what they consider light treatment of John McCain at the expense of other candidates -- especially Barack Obama." In response, AP vice president for corporate communications Ellen Hale sent "elections coverage talking points" to AP managers. Hale suggests pointing to AP's ethics policies, which require reporters to "avoid any political activity, whether they cover politics or not." The talking points cover Fournier's experience and his statement expressing "regret" at "the breezy nature" of a 2004 email to Republican strategist Karl Rove in which Fournier wrote, "Keep up the fight." The talking points also stress when Fournier held different roles at AP and when he worked for the political website HOTSOUP.com. "Later this week," Hale adds, AP "Corporate Communications will go live with a robust new Elections page ... that will provide some real estate to deal with these issues. ... Some of the blogs now are also picking up the drumbeat of dissatisfaction with AP that some members have been voicing with the roll-out of Member choice," a new pricing system for AP content.

Screen capture of a TV ad for Vytorin, taken from YouTubeThree million people worldwide are taking the new, heavily advertised anti-cholesterol drugs Zetia and Vytorin, despite a lack of clinical evidence that they reduce cardiovascular disease or heart attacks, or help patients live longer. Vytorin and Zetia brought in $5.2 billion last year for Merck and Schering-Plough, placing them among the best-selling drugs in the world. The Food and Drug Administration approves many drugs based on whether they perform a specific action, like lowering cholesterol, without requiring long-term trials on whether they extend life or lower disease risks. Other FDA-approved drugs have been found to be ineffective or even dangerous. A possible link between Vytorin and cancer cannot be proved or ruled out after three studies, reports AP. In 1999, the FDA approved the diabetes drug Avandia, because it lowered blood sugar; it was later found to increase heart attacks. But pharmaceutical companies oppose changing the current system. Ken Johnson, senior vice president of the Pharmaceutical Research and Manufacturers of America, says the FDA's approach enables patients "to access life-saving and life-enhancing remedies more quickly."